McKesson Corporation's Stock Analysis

McKesson Secures $2 Billion in Senior Secured Credit Facilities

McKesson Corporation's subsidiaries have entered into a significant credit agreement, which includes a $750 million senior secured term loan facility due in 2031, a $250 million term loan facility due in 2028, and a $1 billion revolving credit facility maturing in 2031. The terms specify that borrowings will incur interest rates based on either the Adjusted Term SOFR Rate or the Base Rate, with initial rates set at 1.250% and 0.250% margins, respectively. The agreement also includes various financial covenants and requirements related to the company's leverage ratios and credit ratings.

The credit facilities are secured by a security interest in the tangible and intangible assets of the Borrower and its material U.S. subsidiaries. The agreement stipulates customary representations, warranties, and covenants, including restrictions on further indebtedness and dividends. Additionally, the Borrower is obligated to pay commitment fees based on its financial performance, and the lenders may engage in other financial transactions with McKesson and its affiliates in the future.

Apr 06, 2026 08:03:56

McKesson Announces Fourth Quarter Earnings Release Schedule

McKesson Corporation will release its fourth quarter fiscal 2026 financial results on May 7, 2026, after market close. A live webcast of the earnings conference call will be hosted by CEO Brian Tyler and CFO Britt Vitalone at 4:30 PM Eastern Time on the same day.

CFO Britt Vitalone is scheduled to participate in several upcoming healthcare conferences, including the Leerink Partners Global Healthcare Conference and the Barclays Global Healthcare Conference on March 11, 2026, as well as the BofA Securities 2026 Healthcare Conference in May 2026. The company has reaffirmed its full-year outlook for fiscal 2026, as previously communicated on February 4, 2026.

Mar 06, 2026 08:04:16

McKesson Announces CFO Retirement and Successor Appointment

Britt J. Vitalone, McKesson's Executive Vice President and Chief Financial Officer, has announced his retirement effective May 28, 2026, after over eight years in the role. He will continue with the company as a non-employee advisor until July 1, 2026, to assist with the transition and the planned separation of McKesson’s Medical Surgical Solutions. Kenny K. Cheung has been appointed as the new CFO, effective May 29, 2026, bringing experience from Sysco Corporation and The Hertz Corporation.

Kenny Cheung's compensation package includes a $3.5 million sign-on bonus and $6 million in restricted stock units, alongside an annual salary of $1.05 million and a potential bonus of 125% of eligible earnings. Additionally, he will receive performance stock units valued at $3.45 million for the fiscal years 2027-2029. The leadership transition occurs as McKesson reports strong financial performance, including record revenue and adjusted operating profit, reflecting ongoing momentum in its business segments.

Mar 05, 2026 08:16:51

McKesson Reports Strong Q3 Results and Adjusted EPS Guidance Increase

McKesson Corporation reported consolidated revenues of $106.2 billion for the third quarter ending December 31, 2025, marking an 11% increase compared to the same period last year. The earnings per diluted share rose to $9.59, up $2.64 from the previous year, while the adjusted earnings per diluted share increased 16% to $9.34. The company generated $1.2 billion in cash flow from operations during the quarter and closed the sale of its Norwegian retail and distribution businesses on January 30, 2026.

For fiscal year 2026, McKesson raised its adjusted earnings per diluted share guidance to a range of $38.80 to $39.20, reflecting anticipated growth of 17% to 19% compared to the prior year. The growth was driven by increased prescription volumes and contributions from recent acquisitions in the Oncology & Multispecialty segment. Additionally, the company reported a total of $2.4 billion returned to shareholders through stock repurchases and dividends in the first nine months of the fiscal year.

Feb 04, 2026 16:05:57

McKesson Reports Record Revenue and Raises Earnings Guidance

McKesson Corporation announced its second-quarter results for the fiscal year 2026, reporting record consolidated revenues of $103.2 billion, a 10% increase compared to the previous year. Earnings per diluted share rose to $8.92, reflecting a significant increase from $1.87 in the same quarter last year. The company also reported adjusted earnings per diluted share of $9.86, which is a 39% increase year-over-year, driven by operational growth and contributions from acquisitions. McKesson generated $2.4 billion in cash flow from operations during the quarter.

Additionally, McKesson raised its full-year adjusted earnings per diluted share guidance to a range of $38.35 to $38.85, indicating projected growth of 16% to 18% compared to the prior year. The increase in guidance follows a previous adjustment made in September 2025. The company continues to focus on growth in its oncology and multispecialty services, which contributed to its strong performance in the quarter. McKesson also returned $1.6 billion to shareholders through stock repurchases and dividends during the first half of the fiscal year.

Nov 05, 2025 16:05:53

McKesson Updates Fiscal 2026 Guidance and Long-Term Financial Targets

On September 23, 2025, McKesson Corporation hosted its Investor Day, where it provided updates on its Fiscal 2026 guidance and long-term financial targets. The company raised its Adjusted Earnings per Diluted Share guidance for Fiscal 2026 to a range of $38.05 to $38.55, up from the previous range of $37.10 to $37.90. Additionally, McKesson introduced a new organizational structure aimed at enhancing growth and shareholder value, while reaffirming its commitment to its strategic priorities in North American pharmaceutical distribution and expanding services in oncology and biopharma.

McKesson also updated its long-term growth targets, increasing the projected growth rate for Adjusted Earnings per Diluted Share from 12%-14% to 13%-16%. The company emphasized its focus on portfolio optimization and strategic growth objectives, which are expected to drive sustainable growth and improve health outcomes. Upcoming investor events include the release of second quarter fiscal 2026 financial results on November 5, 2025, and participation in several healthcare conferences through early 2026.

Sep 23, 2025 08:03:51

McKesson Announces New Segment Reporting Structure for Investors

McKesson Corporation will begin reporting its financial results across four new segments starting in the second quarter of fiscal 2026: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. This reorganization aims to better reflect how the company's Chief Executive Officer allocates resources and assesses performance. The previous financial statements remain unaffected by these changes, which also include the company's Norwegian operations under a new category labeled 'Other.'

Additionally, McKesson is providing supplemental historical financial information in accordance with the new segments for fiscal years 2024 and 2025. This information is intended to assist investors in understanding the impact of the segment changes on the company's financial performance. The company will also present Non-GAAP financial measures, which exclude certain expenses and adjustments, to provide a clearer picture of its operating results and facilitate comparison with other companies in the industry.

Sep 18, 2025 08:00:41

McKesson Reports Q1 Results and Raises EPS Guidance

McKesson Corporation reported consolidated revenues of $97.8 billion for the first quarter ended June 30, 2025, reflecting a 23% increase compared to the previous year. Earnings per diluted share decreased to $6.25, down $0.75 from the prior year, primarily due to a higher provision for bad debts related to the Rite Aid bankruptcy. However, adjusted earnings per diluted share rose by 5% to $8.26, driven by operational growth across the business. The company also announced the completion of acquisitions for controlling interests in PRISM Vision Holdings and Core Ventures, contributing to its expansion in oncology and specialty solutions.

Additionally, McKesson's Board of Directors approved a 15% increase in the quarterly dividend to $0.82 per share, marking the ninth consecutive year of dividend increases. The company raised its fiscal 2026 adjusted earnings per diluted share guidance to a range of $37.10 to $37.90, indicating expected growth of 12% to 15% from the prior year. For the first quarter, McKesson returned $671 million to shareholders, including stock repurchases and dividend payments, while reporting negative free cash flow of $1.1 billion due to cash used for operations and acquisitions.

Aug 06, 2025 16:06:31

McKesson Annual Meeting Vote Results for Shareholders

McKesson Corporation held its Annual Meeting of Shareholders on July 30, 2025. During the meeting, all nominated individuals proposed by the Board of Directors were elected to serve as directors, receiving the necessary votes for approval.

Additionally, shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026. An advisory proposal regarding the compensation of the Company’s named executive officers was also approved by the shareholders.

Aug 01, 2025 08:54:21

McKesson Corporation Announces Offering of $2 Billion in Notes

McKesson Corporation plans to issue $650 million in 4.650% Notes due 2030, $650 million in 4.950% Notes due 2032, and $700 million in 5.250% Notes due 2035, totaling $2 billion. The underwriting will be managed by Barclays Capital Inc., BofA Securities, Deutsche Bank Securities Inc., and J.P. Morgan Securities LLC. The Notes will be issued under an indenture with U.S. Bank Trust Company as trustee and will be available in book-entry form through The Depository Trust Company.

The company has confirmed compliance with registration requirements under the Securities Act, with the registration statement having become effective. McKesson Corporation represents that there have been no material adverse changes in its financial condition since the last reported period. Deloitte & Touche LLP serves as the independent registered public accounting firm for the company, ensuring that the financial statements presented comply with the necessary accounting standards.

May 30, 2025 10:15:08